---
title: 'Clinical Trial Associate/Senior Clinical Trial Associate at Crescent Biopharma'
canonical: 'https://feeny.ai/job/clinical-trial-associate-senior-clinical-trial-associate-crescent-biopharma-9tepp4hjn5fr'
type: 'job'
last_seen: '2026-09-10'
---

# Clinical Trial Associate/Senior Clinical Trial Associate at Crescent Biopharma

- **Company:** Crescent Biopharma
- **Location:** Waltham, MA
- **Employment:** full-time
- **Work type:** onsite
- **Posted:** 2026-07-29
- **Last confirmed live:** 2026-09-10
- **Apply:** https://jobs.lever.co/crescent-biopharma/6d3383ad-55c5-4185-ae8b-ba3250d69ad1

## Job description

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X. We are seeking a CTA/Senior CTA who will work with the Clinical Study Lead and Director of Clinical Operations to support the conduct of clinical trials. You will partner with the Clinical Study Lead to ensure studies are completed on time, within budget, and in compliance with SOPs, FDA regulations and ICH/GCP guidelines. You may independently manage components of clinical studies, including but not limited to vendor oversight, budgets, responsibility for a subset of sites or countries, or phases of the trial (startup period, for example), with oversight.

## Responsibilities

- Support the Clinical Study Lead and Clinical Operations team in the day-to-day operational activities of clinical trials to ensure study objectives, timelines, quality standards, and regulatory requirements are met.
- Support oversight of CROs, vendors, and investigator sites, including review of monitoring visit reports, site communications, and follow-up on study-related actions and issues.
- Maintain study tracking tools for key study documentation (e.g., Form FDA 1572) and operational activities, including site activation, enrollment, monitoring visit status, IRB/EC approvals, safety letter distribution, training compliance, and study milestones.
- Support Trial Master File (eTMF) activities, including document collection, filing, reconciliation, quality control reviews, and inspection readiness efforts.
- Support preparation of study agendas, meeting minutes, action item logs, and study status reports while ensuring effective communication across internal teams, CROs, vendors, and investigator sites.
- Collaborate cross-functionally with Regulatory Affairs, Clinical Supplies, Data Management, Safety, Quality, and other functional areas to support study deliverables and timelines.
- Manage study team training records and ensure compliance with applicable SOPs, regulations, study requirements, and company policies.
- Manage system access requests for study team and site personnel, as needed.
- Communicate and escalate study risks, protocol deviations, operational challenges, and other study-related issues as appropriate.

Education & Experience

- Bachelor’s degree in scientific or related field with 2+ years of experience in Clinical Operations, clinical research or healthcare, or equivalent experience
- Knowledge of FDA regulatory requirements and ICH/GCP guidelines essential
- Demonstrated efficiency in partnering with CROs and vendors
- Computer proficiency (Word, Excel, PowerPoint, Project)
- Works proactively and efficiently in a fast-paced, high change environment
- Must have excellent interpersonal, written and verbal communication skills
- Ability to interact well with various team members and provide value added support to project
- Outstanding organization skills
- Strong analytical, strategic thinking, and problem-solving skills.
- Ability to quickly learn new tools, systems, and processes to improve efficiency

## What We Offer

- Opportunity to join a mission-driven team where you'll contribute to impactful work, take on varied responsibilities, and grow quickly in a dynamic environment
- Competitive compensation, including base salary, performance bonus, and equity
- 100% employer-paid benefits package
- Flexible PTO
- Two, one-week company-wide shutdowns each year
- A commitment to your professional development, with access to resources, mentorship, and growth opportunities

Salary Range

The anticipated salary range for this position is $108,000 to $132,000. The final salary offered will depend on several factors, which may include, but is not limited to relevant years of experience, educational background, and geography.

Additional Description for Pay Transparency:

The final salary offered will depend on several factors, which may include, but is not limited to relevant years of experience, educational background, and geography. Subject to the terms of their respective plans, employees and/or eligible dependents are eligible to participate in the following Company sponsored employee benefit programs: medical, dental, vision, life insurance, short- and long-term disability. Subject to the terms of their respective plans, employees are eligible to participate in the Company’s savings plan (401(k)). This position is eligible to participate in the Company’s long-term incentive program. Subject to the terms of their respective policies and date of hire, Employees are eligible for the following time off benefits: Vacation – Unlimited PTO; Sick time – 10 days per calendar year; Holiday pay, including two Company shut downs; Parental Leave – 16 weeks within one year of the birth/adoption/foster care of a child; FMLA; Military Leave. Additional information can be found - [https://www.crescentbiopharma.com/careers/#benefits](https://nam13.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.crescentbiopharma.com%2Fcareers%2F%23benefits&data=05%7C02%7Clee.schwartz%40crescentbiopharma.com%7Ca470e7b902eb4129a1a808de166a540b%7Cea3ae1e37f5f46159580d5c6e0711b3c%7C0%7C0%7C638972843088266995%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=wT1Z9wts792%2FEuLYQJs2HxHxehSvTRx7cAguiMD4XY0%3D&reserved=0)

Please note: Crescent Biopharma is an Equal Opportunity Employer. We are committed to fostering a diverse, inclusive, and equitable workplace where all individuals are valued and respected. Employment decisions are based on qualifications, merit, and business needs, without regard to race, color, religion, gender, sexual orientation, national origin, disability, veteran status, or any other protected status. Please note, Crescent does not accept unsolicited resumes from external agencies or recruiters. Submission of a resume without a prior written agreement does not create any express or implied contract between Crescent and the agency. Crescent will not pay any fees related to unsolicited resumes.

## #LI-CBIO

## About Crescent Biopharma

## Company Overview
- **One-liner**: Crescent Biopharma is a clinical-stage oncology company developing next-wave cancer therapies, including a PD-1 x VEGF bispecific antibody and antibody-drug conjugates (ADCs) for solid tumors.
- **Entity Type**: Public (IPO in June 2025; ticker not disclosed in available data)
- **Headquarters**: Waltham, Massachusetts, United States (300 Fifth Avenue, Waltham, MA 02451)
- **Founded**: Year not publicly available (company appears to have been active before 2024; IPO in 2025)
- **Founders**: Not publicly available (leadership includes CEO Joshua Brumm, but founder information is not listed)

## Core Business
- **Primary industry/industries**: Oncology biotechnology / Therapeutics
- **Target customers**: B2B – primarily focuses on developing and commercializing cancer therapies, with partnerships and collaborations (e.g., Kelun-Biotech, Paragon Therapeutics)
- **Mission or purpose statement**: “Delivering the next wave of transformative therapies to bring a brighter future for people living with cancer.”

## Products & Services
- **CR-001 (PD-1 x VEGF bispecific antibody)**: A tetravalent bispecific antibody in Phase 1/2 clinical trials (ASCEND) for advanced solid tumors. Designed to exhibit cooperative pharmacology similar to ivonescimab; aims to restore T-cell activity and localize anti-VEGF activity in the tumor microenvironment. Collaboration with Kelun-Biotech for Greater China rights.
- **CR-002 (PD-L1–directed ADC)**: A topoisomerase inhibitor ADC targeting PD-L1, with high internalization. IND planned for mid-2026, with Phase 1/2 trial expected in H2 2026.
- **CR-003 (ITGB6–directed ADC)**: A differentiated ADC targeting integrin beta-6 (ITGB6), with a topoisomerase 1 inhibitor payload. Uses Kthiol conjugation technology. Licensed from Kelun-Biotech for ex-Greater China markets; Phase 1/2 trial ongoing in China.

## Market Standing
- **Valuation/Market Cap**: Not disclosed (public company as of 2025, but no valuation or market cap figure available in provided data)
- **Key Metric**: Total Funding: $585M (including $200M Series A in 2024, $185M Post-IPO Equity in 2025, and $200M Post-IPO Equity in 2025 led by Fairmount Funds Management)
- **Notable Investors/Partners**: Fairmount Funds Management, Venrock Healthcare Capital Partners, Kelun-Biotech (strategic collaboration), Paragon Therapeutics
- **Growth Signals**: Headcount grew 129.6% YoY to 55 employees (LinkedIn); IPO in June 2025; multiple pipeline programs advancing toward IND; expansion into ADC combination trials

## Competitive Advantages
- Focus on established, clinically validated targets (PD-1, VEGF, PD-L1, ITGB6) to reduce risk and accelerate development
- Multi-modality approach (bispecific antibodies + ADCs) enabling combination therapies with potential synergistic effects
- Proprietary ADC technology (Kthiol conjugation) and strategic collaborations for global rights to differentiated assets
- Strong leadership team with deep oncology drug development expertise (former executives from major biopharma)

## Strategic Focus
- Advance CR-001 as a foundational backbone therapy, with initiation of combination trials with ADCs in H2 2026
- Submit IND for CR-002 in mid-2026 and begin Phase 1/2 trials
- Progress CR-003 clinical program and explore additional internal and partnered ADC and immuno-oncology opportunities
- Build a leading oncology company through disciplined execution, leveraging established biology and multiple modalities

## Why Work Here
- **Culture highlights**: “No egos, collaborative spirit,” “roll up sleeves,” “move with urgency,” “data-driven science with patients as true north.” Emphasizes transparency, integrity, and impact.
- **Remote/hybrid/office policy**: Not explicitly stated; headquarters in Waltham, MA, with an office in Rockville, MD. Likely requires on-site presence given the “highly collaborative” and “urgent” culture.
- **Notable perks**: 100% employer-paid medical, dental, vision, short/long-term disability, life insurance; HSA and dependent care FSA; 401(k); subsidized lunch program; flexible vacation and paid holidays including summer and year-end office closures (one week each).
- **Best for**: Bold innovators who want to make a significant impact in oncology drug development, thrive in a fast-paced, transparent environment, and are motivated by patient outcomes.

## Sources
1. [crescentbiopharma.com – Careers](https://www.crescentbiopharma.com/careers/)
2. [crescentbiopharma.com – About](https://www.crescentbiopharma.com/about/)
3. [crescentbiopharma.com – Pipeline](https://www.crescentbiopharma.com/pipeline/)
4. [linkedin.com – Crescent Biopharma](https://www.linkedin.com/company/crescent-biopharma)
5. [jobs.lever.co – Crescent Biopharma](https://jobs.lever.co/crescent-biopharma)

## Other roles at Crescent Biopharma

- [Executive Director/Vice President, Corporate Development](https://feeny.ai/job/executive-director-vice-president-corporate-development-crescent-biopharma-a167et02k0jt) — Waltham, MA
- [Director, Clinical Supply Chain](https://feeny.ai/job/director-clinical-supply-chain-crescent-biopharma-waltham-92w8s0ryzk1d) — Waltham, MA
- [Associate Director/Director, Bioanalysis](https://feeny.ai/job/associate-director-director-bioanalysis-crescent-biopharma-waltham-wfq3aj03vtzf) — Waltham, MA
- [Director, ADC Drug Substance](https://feeny.ai/job/director-adc-drug-substance-crescent-biopharma-waltham-7dyxva49nmt1) — Waltham, MA
- [Director/Senior Director, Drug Product](https://feeny.ai/job/director-senior-director-drug-product-crescent-biopharma-waltham-pj5x6ve5sp22) — Waltham, MA
- [Executive Assistant - R&D](https://feeny.ai/job/executive-assistant-r-d-crescent-biopharma-waltham-th1vr004bn6z) — Waltham, MA
- [Senior Director, Global Medical Affairs](https://feeny.ai/job/senior-director-global-medical-affairs-crescent-biopharma-waltham-hz7hjwnnayha) — Waltham, MA
- [Director/Senior Director, GMP Quality Assurance Operations](https://feeny.ai/job/director-senior-director-gmp-quality-assurance-operations-crescent-biopharma-zt813qk13fnp) — Waltham, MA
- [Director/Senior Director, QMS, Digital QA and GxP Compliance](https://feeny.ai/job/director-senior-director-qms-digital-qa-and-gxp-compliance-crescent-biopharma-brmrgq5qf5xc) — Waltham, MA
- [Manager, CMC Project Management](https://feeny.ai/job/manager-cmc-project-management-crescent-biopharma-waltham-bad0nec61tqz) — Waltham, MA